Eliminating mother-to-child transmission of HBV: progress and challenges in China

doi:10.1007/s11684-020-0744-2

Front. Med.

2020, Vol. 14

Issue (1) : 21-29 https://doi.org/10.1007/s11684-020-0744-2

REVIEW

Eliminating mother-to-child transmission of HBV: progress and challenges in China

Wenzhan Jing, Jue Liu, Min Liu(

)

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

Download: PDF(703 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

China has the world’s largest burden of hepatitis B virus (HBV) infection, but the country has made considerable progress in preventing its mother-to-child transmission (MTCT) in the past three decades. This feat is made possible due to the high coverage of birth-dose hepatitis B vaccine (HepB,>95%), hepatitis B surface antigen (HBsAg) screening for pregnant women (>99%), and hepatitis B immunoglobulin plus HepB for newborns whose mothers are HBsAg positive (>99%). Studies on the optimal antiviral treatment regimen for pregnant women with high HBV-DNA load have also been conducted. However, China still faces challenges in eliminating MTCT of HBV. The overall HBsAg prevalence among pregnant women is considered an intermediate endemic. The prevalence of HBsAg among pregnant women from remote, rural, or ethnic minority areas is higher than that of the national level because of limited health resources and public health education for HBV. The coverage for maternal and child healthcare and immunization services should be improved, especially in western regions. Integration of current services to prevent MTCT of HBV with other relevant health services can increase the acceptability, efficiency, and coverage of these services, particularly in remote areas and ethnic minority areas. By doing so, progress toward key milestones and targets to eliminate hepatitis B as the main public health threat by 2030 can be achieved.

Keywords hepatitis B virus mother-to-child transmission progress challenge

Corresponding Author(s): Min Liu

Just Accepted Date: 27 December 2019 Online First Date: 20 January 2020 Issue Date: 02 March 2020

Cite this article:

Wenzhan Jing,Jue Liu,Min Liu. Eliminating mother-to-child transmission of HBV: progress and challenges in China[J]. Front. Med., 2020, 14(1): 21-29.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-020-0744-2
https://academic.hep.com.cn/fmd/EN/Y2020/V14/I1/21

Fig.1 Major policies and measures to prevent MTCT of HBV in China. HBV, hepatitis B virus; HepB, hepatitis B vaccine; HBsAg, hepatitis B surface antigen; HBIG, hepatitis B immunoglobulin; GAVI, Global Alliance for Vaccine and Immunization; MTCT, mother-to-child transmission; iPMTCT, integrated prevention of mother-to-child transmission; TDF, tenofovir disoproxil fumarate; LdT, tebivudine; LAM, lamivudine.

1	KW Cheung, MTY Seto, TTH Lao. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet 2019; 300(2): 251–259 https://doi.org/10.1007/s00404-019-05190-0 pmid: 31098821
2	Chinese Medical Association Obstetrics and Gynecology Branch. Clinical guidelines for prevention of mother-to-child transmission of hepatitis B virus (1st Edition). Chin J Obstet Gynecol (Zhonghua Fu Chan Ke Za Zhi) 2013; (2): 151–154 (in Chinese)
3	World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: World Health Organization, 2015. (accessed May 15, 2018)
4	World Health Organization. Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization, 2017. (accessed January 12, 2018)
5	YF Liaw, CM Chu. Hepatitis B virus infection. Lancet 2009; 373(9663): 582–592 https://doi.org/10.1016/S0140-6736(09)60207-5 pmid: 19217993
6	FS Wang, JG Fan, Z Zhang, B Gao, HY Wang. The global burden of liver disease: the major impact of China. Hepatology 2014; 60(6): 2099–2108 https://doi.org/10.1002/hep.27406 pmid: 25164003
7	RX Yin, ZH Liu, ZH Liu, J Li, H Zhuang, XG Dou, JL Hou. Getting to zero mother-to-child transmission of hepatitis B virus: dream and challenge. Chin J Hepatol (Zhonghua Gan Zang Bing Za Zhi) 2018; (4): 262–265 (in Chinese)
8	C Trépo, HL Chan, A Lok. Hepatitis B virus infection. Lancet 2014; 384(9959): 2053–2063 https://doi.org/10.1016/S0140-6736(14)60220-8 pmid: 24954675
9	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3(6): 383–403 https://doi.org/10.1016/S2468-1253(18)30056-6 pmid: 29599078
10	World Health Organization. Tenofovir reduces mother-to-child transmission of hepatitis B: new study. Geneva, Switzerland: World Health Organization, 2016. (accessed January 15, 2019)
11	Y Xu, H Liu, Y Wang, R Hao, Z Li, H Song. The next step in controlling HBV in China. BMJ 2013; 347: f4503 https://doi.org/10.1136/bmj.f4503 pmid: 23861426
12	X Liang, S Bi, W Yang, L Wang, G Cui, F Cui, Y Zhang, J Liu, X Gong, Y Chen, F Wang, H Zheng, F Wang, J Guo, Z Jia, J Ma, H Wang, H Luo, L Li, S Jin, SC Hadler, Y Wang. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27(47): 6550–6557 https://doi.org/10.1016/j.vaccine.2009.08.048 pmid: 19729084
13	J Liu, W Liang, W Jing, M Liu. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ 2019; 97(3): 230–238 https://doi.org/10.2471/BLT.18.219469 pmid: 30992636
14	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). 2018. (accessed April 20, 2018)
15	World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Geneva, Switzerland: World Health Organization, 2016. (accessed March 29, 2018)
16	World Health Organization. Regional Office for the Western Pacific. Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific, 2018–2030. Geneva, Switzerland: World Health Organization, 2018. (accessed April 10, 2018)
17	F Cui, X Liang, X Gong, Y Chen, F Wang, H Zheng, Z Wu, N Miao, SC Hadler, YJ Hutin, H Luo, W Yang. Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. Vaccine 2013; 31(Suppl 9): J29–J35 https://doi.org/10.1016/j.vaccine.2012.07.048 pmid: 24331017
18	F Cui, H Luo, F Wang, H Zheng, X Gong, Y Chen, Z Wu, N Miao, M Kane, K Hennessey, SC Hadler, YJ Hutin, X Liang, W Yang. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine 2013; 31(Suppl 9): J36–J42 https://doi.org/10.1016/j.vaccine.2012.11.061 pmid: 24331019
19	National Health Commission of the People’s Republic of China. The National Health Commission held a press conference on July 25, 2017 (in Chinese) (accessed April 10, 2019)
20	National Health Commission of the People’s Republic of China. The 2018 China Health Statistics Yearbook. Beijing: China Union Medical University Press, 2018 (in Chinese)
21	X Liang, S Bi, W Yang, L Wang, G Cui, F Cui, Y Zhang, J Liu, X Gong, Y Chen, F Wang, H Zheng, F Wang, J Guo, Z Jia, J Ma, H Wang, H Luo, L Li, S Jin, SC Hadler, Y Wang. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis 2009; 200(1): 39–47 https://doi.org/10.1086/599332 pmid: 19469708
22	J Cui, L Cao, J Zheng, L Cao, M Duo, Q Xiao. Reported coverage of vaccines in the National Immunization Program of China, 2015. Chin J vacc and imm (Zhongguo Yi Miao He Mian Yi) 2017; (6): 601–607 (in Chinese)
23	F Cui, L Shen, L Li, H Wang, F Wang, S Bi, J Liu, G Zhang, F Wang, H Zheng, X Sun, N Miao, Z Yin, Z Feng, X Liang, Y Wang. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis 2017; 23(5): 765–772 https://doi.org/10.3201/eid2305.161477 pmid: 28418296
24	GL Xia, CB Liu, HL Cao, SL Bi, MY Zhan, CA Su, JH Nan, XQ Qi. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun 1996; 5(1): 62–73 https://doi.org/10.1016/S0928-4346(96)82012-3
25	CL Thio, N Guo, C Xie, KE Nelson, S Ehrhardt. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis 2015; 15(8): 981–985 https://doi.org/10.1016/S1473-3099(15)00158-9 pmid: 26145195
26	National Health Commission of the People’s Republic of China. Comprehensive Prevention of Mother-to-Child Transmission for HIV, Syphilis and Hepatitis B. April, 2015 (in Chinese) (accessed April 22, 2018)
27	AL Wang, YP Qiao, LH Wang, LW Fang, F Wang, X Jin, J Qiu, XY Wang, Q Wang, JL Wu, SH Vermund, L Song. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ 2015; 93(1): 52–56 https://doi.org/10.2471/BLT.14.139626 pmid: 25558108
28	National Health Commission of the People’s Republic of China. Prevention of Mother-to-Child Tansmission for Human Immunodeficiency Virus, Syphilis and Hepatitis B Virus Work Plan. 2011 (in Chinese) (accessed March 28, 2018)
29	A Wang, Y Qiao, L Dou, Q Wang, X Wang, M Su, Z Li, X Huang, Y Yang, X Jin, L Song. Challenges of eliminating mother-to-child transmission of HIV, syphilis and hepatitis B in China: a cross-sectional survey. Lancet 2018; 392(Supplement 1): S55 https://doi.org/10.1016/S0140-6736(18)32684-9
30	Yuhang Government, Zhejiang Province, China. Yuhang Becomes a National Pilot Area to Eliminate of Mother-to-Child Transmission for HIV, syphilis and hepatitis B virus Project. September 2017 (in Chinese) (accessed April 29, 2018)
31	X Lin, Y Guo, A Zhou, Y Zhang, J Cao, M Yang, F Xiao, B Zhang, Y Du. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis. Pediatr Infect Dis J 2014; 33(9): 897–903 https://doi.org/10.1097/INF.0000000000000315 pmid: 25361021
32	H Zou, Y Chen, Z Duan, H Zhang, C Pan. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19(2): e18–e25 https://doi.org/10.1111/j.1365-2893.2011.01492.x pmid: 22239517
33	E Wiseman, MA Fraser, S Holden, A Glass, BL Kidson, LG Heron, MW Maley, A Ayres, SA Locarnini, MT Levy. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190(9): 489–492 https://doi.org/10.5694/j.1326-5377.2009.tb02524.x pmid: 19413519
34	S Peng, Z Wan, T Liu, H Zhu, Y Du. Incidence and risk factors of intrauterine transmission among pregnant women with chronic hepatitis B virus infection. J Clin Gastroenterol 2019; 53(1): 51–57 https://doi.org/10.1097/MCG.0000000000001001 pmid: 29517711
35	G Jourdain, N Ngo-Giang-Huong, L Harrison, L Decker, W Khamduang, C Tierney, N Salvadori, TR Cressey, W Sirirungsi, J Achalapong, P Yuthavisuthi, P Kanjanavikai, OP Na Ayudhaya, T Siriwachirachai, S Prommas, P Sabsanong, A Limtrakul, S Varadisai, C Putiyanun, P Suriyachai, P Liampongsabuddhi, S Sangsawang, W Matanasarawut, S Buranabanjasatean, P Puernngooluerm, C Bowonwatanuwong, T Puthanakit, V Klinbuayaem, S Thongsawat, S Thanprasertsuk, GK Siberry, DH Watts, N Chakhtoura, TV Murphy, NP Nelson, RT Chung, S Pol, N Chotivanich. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 2018; 378(10): 911–923 https://doi.org/10.1056/NEJMoa1708131 pmid: 29514030
36	KP Wei, FC Zhu, JX Liu, L Yan, Y Lu, XJ Zhai, ZJ Chang, Y Zeng, J Li, H Zhuang. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: a prospective cohort study. Vaccine 2018; 36(2): 256–263 https://doi.org/10.1016/j.vaccine.2017.11.037 pmid: 29195717
37	J Hou, F Cui, Y Ding, X Dou, Z Duan, G Han, J Jia, Q Mao, J Li, Z Li, Z Liu, L Wei, Q Xie, X Yang, H Zhang, H Zhuang. Management algorithm for interrupting mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2019; 17(10): 1929–1936.e1 pmid: 30312789
38	H Zheng, GM Zhang, PL Chan, FZ Wang, LE Rodewald, N Miao, XJ Sun, ZD Yin, J Edwards, HQ Wang. Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China. Infect Dis Poverty 2019; 8(1): 57 https://doi.org/10.1186/s40249-019-0568-y pmid: 31269994
39	R Fan, X Yin, Z Liu, Z Liu, G Lau, J Hou. A hepatitis B-free generation in China: from dream to reality. Lancet Infect Dis 2016; 16(10): 1103–1105 https://doi.org/10.1016/S1473-3099(16)30327-9 pmid: 27676339
40	CQ Pan, Z Duan, E Dai, S Zhang, G Han, Y Wang, H Zhang, H Zou, B Zhu, W Zhao, H Jiang; China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374(24): 2324–2334 https://doi.org/10.1056/NEJMoa1508660 pmid: 27305192
41	Q Sheng, Y Ding, B Li, C Han, Y Li, C Zhang, H Bai, J Wang, L Zhao, T Xia, Z An, M Zhang, X Dou. Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China. Int J Med Sci 2018; 15(8): 796–801 https://doi.org/10.7150/ijms.25047 pmid: 30008589
42	M Wang, Q Bian, Y Zhu, Q Pang, L Chang, R Li, BC Tiongson, H Zhang, CQ Pan. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther 2019; 49(2): 211–217 https://doi.org/10.1111/apt.15064 pmid: 30506691
43	J Hou, G Wang, F Wang, J Cheng, H Ren, H Zhuang, J Sun, L Li, J Li, Q Meng, J Zhao, Z Duan, J Jia, H Tang, J Sheng, J Peng, F Lu, Q Xie, L Wei; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol 2017; 5(4): 297–318 https://doi.org/10.14218/JCTH.2016.00019 pmid: 29226097
44	National Health Commission of the People’s Republic of China. Reply to the No. 3268 of the Fourth Session of the Twelfth National People's Congress. 2016 (in Chinese) (accessed April 23, 2018)
45	J Liu, M Liu. Progress and challenges in achieving the WHO goal on ‘Elimination of Hepatitis B by 2030’ in China. Chin J Epidemiol (Zhonghua Liu Xing Bing Xue Za Zhi) 2019; 40(6): 605–609 (in Chinese) pmid: 31238605
46	Ministry of Human Resources and Social Security of the People’s Republic of China. National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List (2017 Edition). 2017 (in Chinese) (accessed March 29, 2018)
47	H Zhao, X Ma, L Zhang, X Liu, L Ciren, C Song. Status of hepatitis B virus infection in pregnant women and infants in Ali, Tibet. China Trop Med (Zhongguo Re Dai Yi Xue) 2018; 18(12): 1218–1221 (in Chinese)
48	F Cui, J Woodring, P Chan, F Xu. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol 2018; 47(5): 1529–1537 https://doi.org/10.1093/ije/dyy077 pmid: 29757383
49	G Li, J Chen, Z Xie, X Li, Y Zhang, J Zhang. HBsAg screening results of 10018 cases of pregnant women, Yunnan, 2013–2016. Mod Prev Med (Xian Dai Yu Fang Yi Xue) 2018; 45(13): 2350–2353, 2441 (in Chinese)
50	National Health Commission of the People’s Republic of China. WHO awards recognition for the prevention and control of hepatitis B in children in China. 2014 (in Chinese) (accessed April 20, 2018)
51	National Health Commission of the People’s Republic of China. National maternal and child health monitoring and annual report communication. 2016 (in Chinese) (accessed July 30, 2018)
52	S Schillie, C Vellozzi, A Reingold, A Harris, P Haber, JW Ward, NP Nelson. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67(1): 1–31 https://doi.org/10.15585/mmwr.rr6701a1 pmid: 29939980
53	National Health Commission of the People’s Republic of China. The 2019 China Health Statistics Yearbook. Beijing: China Union Medical University Press, 2019 (in Chinese)
54	National Health Commission of the People’s Republic of China. National maternal and child health monitoring and annual report communication. 2018 (in Chinese) (accessed July 30, 2019)
55	H Zhang, CQ Pan, Q Pang, R Tian, M Yan, X Liu. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 2014; 60(2): 468–476 https://doi.org/10.1002/hep.27034 pmid: 25187919
56	NA Terrault, NH Bzowej, KM Chang, JP Hwang, MM Jonas, MH Murad; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63(1): 261–283 https://doi.org/10.1002/hep.28156 pmid: 26566064
57	NA Terrault, ASF Lok, BJ McMahon, KM Chang, JP Hwang, MM Jonas, RS Brown Jr, NH Bzowej, JB Wong. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560–1599 https://doi.org/10.1002/hep.29800 pmid: 29405329
58	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370–398 https://doi.org/10.1016/j.jhep.2017.03.021 pmid: 28427875
59	World Health Organization. WHO begins guideline development to stop mother-to-child transmission of hepatitis B. Geneva, Switzerland: World Health Organization, 2019. (accessed October 20, 2019)

[1]	Shasha Zhu, Huimin Zhang, Li Bai. NKT cells in liver diseases[J]. Front. Med., 2018, 12(3): 249-261.
[2]	Hongbing Shen. Low-dose CT for lung cancer screening: opportunities and challenges[J]. Front. Med., 2018, 12(1): 116-121.
[3]	Aixiu Qiao,Feng Gu,Xiaojing Guo,Xinmin Zhang,Li Fu. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications[J]. Front. Med., 2016, 10(1): 33-40.
[4]	Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[5]	James S. Park,Calvin Pan. Current recommendations of managing HBV infection in preconception or pregnancy[J]. Front. Med., 2014, 8(2): 158-165.
[6]	Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan. New perspective on the natural course of chronic HBV infection[J]. Front. Med., 2014, 8(2): 129-134.
[7]	Yan Du, Jiaxin Xie, Wenjun Chang, Yifang Han, Guangwen Cao. Genome-wide association studies: inherent limitations and future challenges[J]. Front Med, 2012, 6(4): 444-450.
[8]	Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG, . Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma[J]. Front. Med., 2010, 4(4): 419-429.
[9]	Lei CHEN, Liang HU, Liang LI, Yuan LIU, Qian-Qian TU, Yan-Xin CHANG, He-Xin YAN, Meng-Chao WU, Hong-Yang WANG, . Dysregulation of β-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas[J]. Front. Med., 2010, 4(4): 399-411.
[10]	Hong-Zhu LU MD, Dan LIU BM, Qi-Hong FAN BM, Jian-Hua ZHOU MD, . Hepatitis B virus X protein upregulates tumor necrosis factor-α expression of rat mesangial cell line via ERKs pathway[J]. Front. Med., 2010, 4(1): 106-111.
[11]	Li-Feng LIU MD, PhD, Qiong CHEN MD, PhD, Ying CHANG MD, PhD, Ju-Sheng LIN MD, PhD, Jin-Liang ZHANG MM, . Cyclooxygenase-2 gene-1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people[J]. Front. Med., 2010, 4(1): 90-95.
[12]	Yuanyuan LIN MD, Xiaoming CHENG MS, Yuhu SONG MD, Peiyuan LI MD, Ying CHANG MM, Jinjian YAO MD, Jusheng LIN MD, PhD, Li ZHOU PhD, Leiming XU PhD, . Construction and expression of hepatitis B virus vector encoding TC-tagged core protein[J]. Front. Med., 2009, 3(4): 396-402.
[13]	Gang LI MD , Xiaojia XIONG MM , . MicroRNAs and hepatitis viruses[J]. Front. Med., 2009, 3(3): 265-270.
[14]	Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM , . Preparation, identification, and clinical application of anti-HBs monoclonal antibody that binds both wild-type and immune escape mutant HBsAgs[J]. Front. Med., 2009, 3(3): 277-283.

Viewed

Full text

Abstract

Cited

Shared

Discussed